Issue 5, 2025
From the journal:

Nanoscale

Correction: Camptothecin-based prodrug nanomedicines for cancer therapy

Renshuai Zhang,a   Jing Yu,b   Zhu Guo,*ac   Hongfei Jiang*a  and  Chao Wang*a  

* Corresponding authors

a Cancer Institute of The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266061, China
E-mail: guozhugz@126.com, jianghongfei@qdu.edu.cn, wangchao@qdu.edu.cn

b Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao, China

c The Affiliated Hospital of Qingdao University, Qingdao 266061, China

Abstract

Correction for ‘Camptothecin-based prodrug nanomedicines for cancer therapy’ by Renshuai Zhang et al., Nanoscale, 2023, 15, 17658–17697, https://doi.org/10.1039/D3NR04147F.

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D4NR90241F
Article type
Correction
Submitted
11 Dec 2024
Accepted
11 Dec 2024
First published
09 Jan 2025
This article is Open Access
Creative Commons BY license

Nanoscale, 2025,17, 2912-2912

Permissions

Request permissions

Correction: Camptothecin-based prodrug nanomedicines for cancer therapy

R. Zhang, J. Yu, Z. Guo, H. Jiang and C. Wang, Nanoscale, 2025, 17, 2912 DOI: 10.1039/D4NR90241F

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements